Canopy Growth Corp Stock Price, News & Analysis

Canopy Growth (Nasdaq: CGC) has appointed Miles Worne as Managing Director of European Markets, effective August 11, 2025. Worne, who previously served as President of Curaleaf International, brings over 20 years of experience in cannabis, healthcare, and consumer sectors.

The appointment aligns with Canopy Growth's strategic focus on European expansion, particularly in established medical markets. The company's European operations are supported by EU-GMP certified supply from its Kincardine facility, processing capabilities at St. Leon-Rot in Germany, and a global supply chain infrastructure.

Canopy Growth (NASDAQ:CGC) has announced a significant debt reduction initiative through an agreement with its lenders. The company will make three prepayments totaling US$50 million to reduce its Senior Secured Term Loan by March 31, 2026.

The prepayments will be made in three installments: US$25 million by July 31, 2025, US$10 million by December 31, 2025, and US$15 million by March 31, 2026. This debt reduction is expected to lower the company's annual cash interest expense by US$6.5 million.

Additionally, Canopy USA received consent to secure US$22 million in additional funding for Acreage Holdings and its subsidiaries.

Canopy Growth (NASDAQ:CGC) has scheduled its first quarter fiscal 2026 financial results release for August 8, 2025, before market open. The company will host an audio webcast at 10:00 AM ET on the same day, featuring CEO Luc Mongeau and Interim CFO Tom Stewart.

The webcast will be available live and accessible for replay until November 6, 2025 at 11:59 PM ET through the company's online portal.

Canopy Growth (Nasdaq: CGC) has launched Deep Space Infused pre-rolls, combining high-quality flower with liquid diamonds and THCA diamonds to achieve THC levels above 60%. The product comes in a 3x0.5g format with two flavors: Milky Way Melon Infused and Big Bang Berry Infused.

The launch is part of Canopy's strategy to expand in the fast-growing pre-roll category, particularly in the infused segment. This follows recent Deep Space beverage and gummy innovations, building on the success of Claybourne's Frosted Flyers launched in November 2024.

The products are now available at licensed retailers across select regions in Canada, including the Spectrum Therapeutics online store for medical consumers.

Canopy Growth (Nasdaq: CGC) has appointed Tom Stewart as Interim Chief Financial Officer, effective immediately. Stewart, who joined the company in 2019 as Chief Accounting Officer, brings over 20 years of experience in operational finance and accounting leadership, including 10 years at Constellation Brands.

Stewart succeeds Judy Hong, who served as CFO since April 2022 and helped improve the company's capital structure. The appointment aligns with Canopy Growth's FY26 strategy, focusing on operational efficiency, disciplined capital management, and building a sustainable, performance-led business. The company has initiated a search for a permanent CFO.

Storz & Bickel, a subsidiary of Canopy Growth Corporation (NASDAQ: CGC), has been awarded 'Equipment Provider of the Year' at the 2025 Business of Cannabis Awards during the Cannabis Europa conference in London.

The award recognizes the company's excellence in vaporization technology, highlighting products like the iconic VOLCANO tabletop vaporizer and the new VENTY device, which features 20-second heat-up and adjustable airflow up to 20 L/min. Storz & Bickel's vaporizers are available in over 120 countries and comply with ISO 13485 standards.

The company has also received multiple other recent accolades, including "Vaporizer of the Year" at The EMJAYs and "Best Portable Vaporizer" by Vaping360 for the VENTY device.

Canopy Growth (CGC) reported Q4 FY2025 and full-year results showing mixed performance. Q4 net revenue decreased 11% YoY to $65M, while Canada cannabis revenue grew 4%, led by 13% growth in medical cannabis. The company reduced total debt by $293M (49%) during FY2025. Operating loss improved 83% to $18M in Q4, with Adjusted EBITDA loss improving 39% to $9M. The company implemented strategic changes including unifying global medical cannabis operations and identifying $20M in cost savings. Storz & Bickel revenue declined 23% in Q4 but grew 4% for the full year. International cannabis revenue fell 35% in Q4 due to regulatory challenges in Poland. Management is focused on achieving positive Adjusted EBITDA in the near term through growth in medical cannabis, improved margins in adult-use, and cost reductions.

Canopy Growth Corporation (NASDAQ: CGC) has announced it will release its fourth quarter and fiscal year 2025 financial results on May 30, 2025, before market open. Following the release, CEO Luc Mongeau and CFO Judy Hong will host an audio webcast at 10 AM ET. The webcast will be available for replay until August 28, 2025.

Canopy Growth (NASDAQ: CGC) has launched new cannabis products targeting Canada's highest-demand adult-use categories. The company is focusing on four key formats: vapes, high-THC flower, pre-rolls, and edibles. Key product launches include:

- Advanced all-in-one vapes with CCELL technology featuring built-in displays for Tweed and 7ACRES brands

- New high-THC flower strains (Sour Sucker Mints and Blood Orange Kush) testing above 28% THC with 3.25-4% total terpenes

- Expanded pre-roll offerings including new Claybourne Frosted Flyers flavors and 7ACRES live resin-infused products

- Deep Space's entry into the edibles category with 10mg THC gummies containing natural caffeine